Cardio-Renal Metabolic Syndrome: An Integrated Approach to Prevention and Management

Nov 10, 2025Cureus

Preventing and Managing the Combined Heart, Kidney, and Metabolism Disorder

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

The prevalence of cardio-renal metabolic syndrome (CRMS) continues to rise globally, particularly in low- and middle-income countries.

CRMS is characterized by the interaction of metabolic risk factors, chronic kidney disease, and cardiovascular disease.
It is associated with significantly increased morbidity and premature mortality due to overlapping conditions.
Current diagnostic advancements include novel biomarkers and imaging techniques that enhance early detection.
Preventive strategies focus on lifestyle changes, dietary modifications, weight loss, and smoking cessation.
Pharmacological therapies such as SGLT2 inhibitors and GLP-1 receptor agonists provide cardio-renal protection.
Emerging approaches in precision medicine and artificial intelligence may improve risk stratification and treatment.

AI simplified

Cardio-renal metabolic syndrome (CRMS), also termed cardiovascular-kidney-metabolic (CKM) syndrome, represents the convergence of metabolic risk factors, chronic kidney disease (CKD), and cardiovascular disease (CVD), underpinned by insulin resistance (IR), neurohormonal activation, oxidative stress, and chronic inflammation. This narrative review synthesizes current evidence on the epidemiology, pathophysiology, diagnostic approaches, prevention, and management of CRMS. Globally, CRMS prevalence continues to rise, driven by aging populations, urbanization, obesity, and diabetes, with disproportionate effects in low- and middle-income countries. The syndrome is associated with substantially increased morbidity and premature mortality, reflecting the synergistic effects of overlapping conditions. Advances in diagnostic evaluation, including novel biomarkers and imaging modalities, have improved early detection, but significant gaps remain. Preventive strategies emphasize lifestyle modification, dietary change, weight reduction, and smoking cessation, complemented by pharmacological therapies such as sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, mineralocorticoid receptor antagonists (MRAs), and renin-angiotensin-aldosterone system (RAAS) blockade, all of which demonstrate cardio-renal protection. Non-pharmacological approaches, including bariatric surgery and renal replacement therapies (RRTs), add to the therapeutic armamentarium. Looking ahead, precision medicine, artificial intelligence (AI)-driven prognostic tools, and emerging biomarkers offer opportunities to refine risk stratification and treatment. An integrated, multidisciplinary framework is essential to reduce the escalating global burden and improve patient-centered outcomes in CRMS.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text ↗

Cardio-Renal Metabolic Syndrome: An Integrated Approach to Prevention and Management

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief